Skip to main content
Ulka Vaishampayan, MD, Oncology, Ann Arbor, MI

UlkaNitinVaishampayanMD

Oncology • Ann Arbor, MI

Genitourinary Oncology

Director of Phase I at Rogel Cancer Center Professor of medicine/oncology University of Michigan Ann Arbor MI

Join to view full profile

Dr. Vaishampayan is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Vaishampayan's full profile

Already have an account?

  • Office

    7217 Rogel cancer center
    1500 E Medical center dr
    Ann Arbor, MI 48109
    Phone+1 734-647-8903
    Fax+1 734-232-9357

Summary

  • Dr. Ulka Vaishampayan is an oncologist practicing at University of Michigan Ann Arbor MI. She received her medical degree from B.J. Medical College - University of Pune and has been in practice 24 years. She specializes in medical oncology and is experienced in urologic and general medical oncology. Her research focus is clinical trials and drug development and novel biomarkers in cancer.

Education & Training

  • Detroit Medical Center/Wayne State University
    Detroit Medical Center/Wayne State UniversityFellowship, Hematology and Medical Oncology, 1997 - 2000
  • Wayne State University School of Medicine
    Wayne State University School of MedicineResidency, Internal Medicine, 1994 - 1997
  • B.J. Medical College - University of Pune
    B.J. Medical College - University of PuneClass of 1993

Certifications & Licensure

  • MI State Medical License
    MI State Medical License 1997 - 2026
  • American Board of Internal Medicine Medical Oncology

Clinical Trials

Publications & Presentations

PubMed

Lectures

  • Intravenous administration of ALKS 4230 as monotherapy and in combination with pembrolizumab in a phase I study of patients with advanced solid tumors. 
    2019 ASCO Annual Meeting - 6/1/2019
  • Is a clinical biomarker predictive of outcomes with immune checkpoint inhibitor (ICI) therapy in a phase I patient population. 
    2019 ASCO Annual Meeting - 6/1/2019
  • A phase 1/2 study evaluating the efficacy and safety of the oral CXCR4 inhibitor X4P-001 in combination with axitinib in patients with advanced renal cell carcinoma. 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
  • Join now to see all

Press Mentions

  • Mural Oncology Announces Publication Highlighting Promising Clinical Antitumor Activity Shown in Its ARTISTRY-1 Clinical Trial of Nemvaleukin, Its Lead Engineered Fusion Protein, in the Journal for ImmunoTherapy of Cancer
    Mural Oncology Announces Publication Highlighting Promising Clinical Antitumor Activity Shown in Its ARTISTRY-1 Clinical Trial of Nemvaleukin, Its Lead Engineered Fusion Protein, in the Journal for ImmunoTherapy of CancerNovember 20th, 2024
  • Major Bladder Cancer Study Disappoints: “We Won’t Have a Whole Lot of Other Treatment Options”
    Major Bladder Cancer Study Disappoints: “We Won’t Have a Whole Lot of Other Treatment Options”June 3rd, 2024
  • Rare Disease Day with Thomas Abrams, MD; Maria Badillo, MSN, RN, OCN®, CCRP; And Ulka Vaishampayan, MD
    Rare Disease Day with Thomas Abrams, MD; Maria Badillo, MSN, RN, OCN®, CCRP; And Ulka Vaishampayan, MDMarch 20th, 2023
  • Join now to see all

Professional Memberships

Dr. Ulka Vaishampayan, Dr. Ulka Vaishampayan, MD, Dr. U Vaishampayan, Dr. Ulka Nitin Vaishampayan